New drug shows promise in combination with cabozantinib for the treatment of advanced kidney cancer
Results from a phase 1 clinical trial looking at CB-839, [...]
Atezolizumab plus bevacizumab combination is positive for untreated metastatic kidney cancer
The combination of immunotherapy atezolizumab (Tecentriq) with targeted therapy bevacizumab [...]
Quality of life outcomes similar for cabozantinib and everolimus
Data from the phase 3 METEOR trial published in the Journal [...]
Flagship cancer fund underspent amid uncertainty over its future
The following article about the underspend by the Cancer Drugs [...]
Combination immunotherapy: the new standard of care for metastatic kidney cancer
The following video interviews discuss combinations of immunotherapy drugs and [...]
Britain fails to narrow the cancer survival gap behind the best in the world
A new global study involving 37 million cancer patients in [...]
Stereotactic ablative radiotherapy (SABR) is an effective treatment for primary kidney cancer
Data from a pooled analysis published in the journal Cancer [...]
Tessa Jowell’s moving speech calling for a change in the way the NHS treats cancer
Baroness Tessa Jowell received a standing ovation after delivering moving [...]
New Cancer Drugs Fund benefiting thousands of patients and releasing £140m for the NHS
NHS England have released an update on the new Cancer [...]
The benefits of immunotherapy combinations
This article, published in Nature just before Christmas, gives a [...]
